{"id":5928,"date":"2022-04-08T03:48:42","date_gmt":"2022-04-08T03:48:42","guid":{"rendered":"https:\/\/eghonguzmanb.cl\/site\/?p=5928"},"modified":"2022-04-08T03:48:42","modified_gmt":"2022-04-08T03:48:42","slug":"chile-se-convierte-en-un-polo-atractivo-para-la-industria-biofarmaceutica","status":"publish","type":"post","link":"https:\/\/eghonguzmanb.cl\/site\/2022\/04\/08\/chile-se-convierte-en-un-polo-atractivo-para-la-industria-biofarmaceutica\/","title":{"rendered":"CHILE SE CONVIERTE EN UN POLO ATRACTIVO PARA LA INDUSTRIA BIOFARMAC\u00c9UTICA"},"content":{"rendered":"\n<h2 class=\"wp-block-heading\">CHILE SE CONVIERTE EN UN POLO ATRACTIVO PARA LA INDUSTRIA BIOFARMAC\u00c9UTICA<\/h2>\n\n\n\n<figure class=\"wp-block-image\"><a href=\"https:\/\/asocimed.cl\/portfolio\/chile-se-convierte-en\/\"><img decoding=\"async\" src=\"https:\/\/asocimed.cl\/portfolio\/chile-se-convierte-en\/\" alt=\"\"\/><\/a><\/figure>\n\n\n\n<p><a href=\"https:\/\/asocimed.cl\/wp-content\/uploads\/2018\/06\/Biopharmaceutical-Competitiveness-Investment-BCI-Survey-1.jpg\"><\/a>El Presidente de nuestra Instituci\u00f3n, el&nbsp;Dr. Eghon Guzm\u00e1n, fue invitado este 10 de mayo de 2018 a la presentaci\u00f3n del estudio 2017 Biopharmaceutical Competitiveness &amp; Investment (BCI) Survey.<strong>CHILE SE CONVIERTE EN UN POLO ATRACTIVO<\/strong><strong>PARA LA INDUSTRIA BIOFARMAC\u00c9UTICA Y LA<\/strong><strong>INVESTIGACI\u00d3N CL\u00cdNICA A NIVEL MUNDIAL<\/strong><strong>Estudio 2017 sobre Inversi\u00f3n y Competitividad en Biomedicina, patrocinado por PhRMA y&nbsp;FIFARMA, demostr\u00f3 que los pa\u00edses latinoamericanos podr\u00edan aumentar sustancialmente el nivel&nbsp;de inversi\u00f3n en la materia y que el pa\u00eds l\u00edder en la regi\u00f3n es Chile.<\/strong>&nbsp;En un encuentro organizado por la C\u00e1mara de la Innovaci\u00f3n Farmac\u00e9utica de Chile, (CIF) se&nbsp;present\u00f3 el estudio Biopharmaceutical Competitiveness and Investment (BCI) Survey 2017 que&nbsp;analiza, con base en la opini\u00f3n de 500 ejecutivos de las principales multinacionales que operan&nbsp;tanto en econom\u00edas desarrolladas como emergentes, el grado de atractivo y competitividad para&nbsp;el desarrollo de la industria biofarmac\u00e9utica, midiendo el grado de confianza que ellos tienen en 5&nbsp;\u00e1reas \u2013 que incluyen el grado de sofisticaci\u00f3n de la infraestructura local de investigaci\u00f3n y&nbsp;desarrollo, capacidades regulatorias, protecci\u00f3n de propiedad intelectual y din\u00e1micas de mercado&nbsp;\u2013 y traduci\u00e9ndolo en un puntaje cuantitativo.<a href=\"https:\/\/asocimed.cl\/wp-content\/uploads\/2018\/06\/comunicado-de-prensa-BCI-survey.docx\"><strong>Descargar Comunicado de Prensa BCI Survey<\/strong><\/a>Imagenes del Evento.<\/p>\n\n\n\n<figure class=\"wp-block-image\"><a href=\"https:\/\/asocimed.cl\/portfolio\/chile-se-convierte-en\/#\"><img decoding=\"async\" src=\"https:\/\/asocimed.cl\/wp-content\/uploads\/2018\/06\/IMG_8784_low-270x270.jpg\" alt=\"Biopharmaceutical Competitiveness &amp; Investment (BCI) Survey\"\/><\/a><\/figure>\n\n\n\n<p><a href=\"https:\/\/asocimed.cl\/wp-content\/uploads\/2018\/06\/IMG_8784_low.jpg\"><\/a><\/p>\n\n\n\n<figure class=\"wp-block-image\"><a href=\"https:\/\/asocimed.cl\/portfolio\/chile-se-convierte-en\/#\"><img decoding=\"async\" src=\"https:\/\/asocimed.cl\/wp-content\/uploads\/2018\/06\/IMG_8785_low-270x270.jpg\" alt=\"Biopharmaceutical Competitiveness &amp; Investment (BCI) Survey\"\/><\/a><\/figure>\n\n\n\n<p><a href=\"https:\/\/asocimed.cl\/wp-content\/uploads\/2018\/06\/IMG_8785_low.jpg\"><\/a><\/p>\n\n\n\n<figure class=\"wp-block-image\"><a href=\"https:\/\/asocimed.cl\/portfolio\/chile-se-convierte-en\/#\"><img decoding=\"async\" src=\"https:\/\/asocimed.cl\/wp-content\/uploads\/2018\/06\/IMG_8787_low-270x270.jpg\" alt=\"Biopharmaceutical Competitiveness &amp; Investment (BCI) Survey\"\/><\/a><\/figure>\n\n\n\n<p><a href=\"https:\/\/asocimed.cl\/wp-content\/uploads\/2018\/06\/IMG_8787_low.jpg\"><\/a><\/p>\n\n\n\n<figure class=\"wp-block-image\"><a href=\"https:\/\/asocimed.cl\/portfolio\/chile-se-convierte-en\/#\"><img decoding=\"async\" src=\"https:\/\/asocimed.cl\/wp-content\/uploads\/2018\/06\/IMG_8792_low-270x270.jpg\" alt=\"Biopharmaceutical Competitiveness &amp; Investment (BCI) Survey\"\/><\/a><\/figure>\n\n\n\n<p><a href=\"https:\/\/asocimed.cl\/wp-content\/uploads\/2018\/06\/IMG_8792_low.jpg\"><\/a><\/p>\n\n\n\n<figure class=\"wp-block-image\"><a href=\"https:\/\/asocimed.cl\/portfolio\/chile-se-convierte-en\/#\"><img decoding=\"async\" src=\"https:\/\/asocimed.cl\/wp-content\/uploads\/2018\/06\/IMG_8805_low-270x270.jpg\" alt=\"Biopharmaceutical Competitiveness &amp; Investment (BCI) Survey\"\/><\/a><\/figure>\n\n\n\n<p><a href=\"https:\/\/asocimed.cl\/wp-content\/uploads\/2018\/06\/IMG_8805_low.jpg\"><\/a><\/p>\n\n\n\n<figure class=\"wp-block-image\"><a href=\"https:\/\/asocimed.cl\/portfolio\/chile-se-convierte-en\/#\"><img decoding=\"async\" src=\"https:\/\/asocimed.cl\/wp-content\/uploads\/2018\/06\/IMG_8817_low-270x270.jpg\" alt=\"Biopharmaceutical Competitiveness &amp; Investment (BCI) Survey\"\/><\/a><\/figure>\n\n\n\n<p><a href=\"https:\/\/asocimed.cl\/wp-content\/uploads\/2018\/06\/IMG_8817_low.jpg\"><\/a><\/p>\n\n\n\n<figure class=\"wp-block-image\"><a href=\"https:\/\/asocimed.cl\/portfolio\/chile-se-convierte-en\/#\"><img decoding=\"async\" src=\"https:\/\/asocimed.cl\/wp-content\/uploads\/2018\/06\/IMG_8820_low-270x270.jpg\" alt=\"Biopharmaceutical Competitiveness &amp; Investment (BCI) Survey\"\/><\/a><\/figure>\n\n\n\n<p><a href=\"https:\/\/asocimed.cl\/wp-content\/uploads\/2018\/06\/IMG_8820_low.jpg\"><\/a><\/p>\n\n\n\n<figure class=\"wp-block-image\"><a href=\"https:\/\/asocimed.cl\/portfolio\/chile-se-convierte-en\/#\"><img decoding=\"async\" src=\"https:\/\/asocimed.cl\/wp-content\/uploads\/2018\/06\/IMG_8825_low-270x270.jpg\" alt=\"Biopharmaceutical Competitiveness &amp; Investment (BCI) Survey\"\/><\/a><\/figure>\n\n\n\n<p><a href=\"https:\/\/asocimed.cl\/wp-content\/uploads\/2018\/06\/IMG_8825_low.jpg\"><\/a><\/p>\n\n\n\n<figure class=\"wp-block-image\"><a href=\"https:\/\/asocimed.cl\/portfolio\/chile-se-convierte-en\/#\"><img decoding=\"async\" src=\"https:\/\/asocimed.cl\/wp-content\/uploads\/2018\/06\/IMG_8827_low-270x270.jpg\" alt=\"Biopharmaceutical Competitiveness &amp; Investment (BCI) Survey\"\/><\/a><\/figure>\n\n\n\n<p><a href=\"https:\/\/asocimed.cl\/wp-content\/uploads\/2018\/06\/IMG_8827_low.jpg\"><\/a><\/p>\n\n\n\n<figure class=\"wp-block-image\"><a href=\"https:\/\/asocimed.cl\/portfolio\/chile-se-convierte-en\/#\"><img decoding=\"async\" src=\"https:\/\/asocimed.cl\/wp-content\/uploads\/2018\/06\/IMG_8843_low-270x270.jpg\" alt=\"Biopharmaceutical Competitiveness &amp; Investment (BCI) Survey\"\/><\/a><\/figure>\n\n\n\n<p><a href=\"https:\/\/asocimed.cl\/wp-content\/uploads\/2018\/06\/IMG_8843_low.jpg\"><\/a><\/p>\n\n\n\n<figure class=\"wp-block-image\"><a href=\"https:\/\/asocimed.cl\/portfolio\/chile-se-convierte-en\/#\"><img decoding=\"async\" src=\"https:\/\/asocimed.cl\/wp-content\/uploads\/2018\/06\/IMG_8859_low-270x270.jpg\" alt=\"Biopharmaceutical Competitiveness &amp; Investment (BCI) Survey\"\/><\/a><\/figure>\n\n\n\n<p><a href=\"https:\/\/asocimed.cl\/wp-content\/uploads\/2018\/06\/IMG_8859_low.jpg\"><\/a><\/p>\n\n\n\n<figure class=\"wp-block-image\"><a href=\"https:\/\/asocimed.cl\/portfolio\/chile-se-convierte-en\/#\"><img decoding=\"async\" src=\"https:\/\/asocimed.cl\/wp-content\/uploads\/2018\/06\/IMG_8871_low-270x270.jpg\" alt=\"Biopharmaceutical Competitiveness &amp; Investment (BCI) Survey\"\/><\/a><\/figure>\n\n\n\n<p><a href=\"https:\/\/asocimed.cl\/wp-content\/uploads\/2018\/06\/IMG_8871_low.jpg\"><\/a><\/p>\n\n\n\n<figure class=\"wp-block-image\"><a href=\"https:\/\/asocimed.cl\/portfolio\/chile-se-convierte-en\/#\"><img decoding=\"async\" src=\"https:\/\/asocimed.cl\/wp-content\/uploads\/2018\/06\/IMG_8876_low-270x270.jpg\" alt=\"Biopharmaceutical Competitiveness &amp; Investment (BCI) Survey\"\/><\/a><\/figure>\n\n\n\n<p><a href=\"https:\/\/asocimed.cl\/wp-content\/uploads\/2018\/06\/IMG_8876_low.jpg\"><\/a><\/p>\n\n\n\n<figure class=\"wp-block-image\"><a href=\"https:\/\/asocimed.cl\/portfolio\/chile-se-convierte-en\/#\"><img decoding=\"async\" src=\"https:\/\/asocimed.cl\/wp-content\/uploads\/2018\/06\/IMG_8880_low-270x270.jpg\" alt=\"Biopharmaceutical Competitiveness &amp; Investment (BCI) Survey\"\/><\/a><\/figure>\n\n\n\n<p><a href=\"https:\/\/asocimed.cl\/wp-content\/uploads\/2018\/06\/IMG_8880_low.jpg\"><\/a><\/p>\n\n\n\n<figure class=\"wp-block-image\"><a href=\"https:\/\/asocimed.cl\/portfolio\/chile-se-convierte-en\/#\"><img decoding=\"async\" src=\"https:\/\/asocimed.cl\/wp-content\/uploads\/2018\/06\/IMG_8899_low-270x270.jpg\" alt=\"Biopharmaceutical Competitiveness &amp; Investment (BCI) Survey\"\/><\/a><\/figure>\n\n\n\n<p><a href=\"https:\/\/asocimed.cl\/wp-content\/uploads\/2018\/06\/IMG_8899_low.jpg\"><\/a><\/p>\n\n\n\n<figure class=\"wp-block-image\"><a href=\"https:\/\/asocimed.cl\/portfolio\/chile-se-convierte-en\/#\"><img decoding=\"async\" src=\"https:\/\/asocimed.cl\/wp-content\/uploads\/2018\/06\/IMG_8938_low-270x270.jpg\" alt=\"Biopharmaceutical Competitiveness &amp; Investment (BCI) Survey\"\/><\/a><\/figure>\n\n\n\n<p><a href=\"https:\/\/asocimed.cl\/wp-content\/uploads\/2018\/06\/IMG_8938_low.jpg\"><\/a><\/p>\n\n\n\n<figure class=\"wp-block-image\"><a href=\"https:\/\/asocimed.cl\/portfolio\/chile-se-convierte-en\/#\"><img decoding=\"async\" src=\"https:\/\/asocimed.cl\/wp-content\/uploads\/2018\/06\/IMG_8951_low-270x270.jpg\" alt=\"Biopharmaceutical Competitiveness &amp; Investment (BCI) Survey\"\/><\/a><\/figure>\n\n\n\n<p><a href=\"https:\/\/asocimed.cl\/wp-content\/uploads\/2018\/06\/IMG_8951_low.jpg\"><\/a><\/p>\n\n\n\n<figure class=\"wp-block-image\"><a href=\"https:\/\/asocimed.cl\/portfolio\/chile-se-convierte-en\/#\"><img decoding=\"async\" src=\"https:\/\/asocimed.cl\/wp-content\/uploads\/2018\/06\/IMG_8969_low-270x270.jpg\" alt=\"Biopharmaceutical Competitiveness &amp; Investment (BCI) Survey\"\/><\/a><\/figure>\n\n\n\n<p><a href=\"https:\/\/asocimed.cl\/wp-content\/uploads\/2018\/06\/IMG_8969_low.jpg\"><\/a><\/p>\n\n\n\n<figure class=\"wp-block-image\"><a href=\"https:\/\/asocimed.cl\/portfolio\/chile-se-convierte-en\/#\"><img decoding=\"async\" src=\"https:\/\/asocimed.cl\/wp-content\/uploads\/2018\/06\/IMG_8974_low-270x270.jpg\" alt=\"Biopharmaceutical Competitiveness &amp; Investment (BCI) Survey\"\/><\/a><\/figure>\n\n\n\n<p><a href=\"https:\/\/asocimed.cl\/wp-content\/uploads\/2018\/06\/IMG_8974_low.jpg\"><\/a><\/p>\n\n\n\n<figure class=\"wp-block-image\"><a href=\"https:\/\/asocimed.cl\/portfolio\/chile-se-convierte-en\/#\"><img decoding=\"async\" src=\"https:\/\/asocimed.cl\/wp-content\/uploads\/2018\/06\/IMG_9009_low-270x270.jpg\" alt=\"Biopharmaceutical Competitiveness &amp; Investment (BCI) Survey\"\/><\/a><\/figure>\n\n\n\n<p><a href=\"https:\/\/asocimed.cl\/wp-content\/uploads\/2018\/06\/IMG_9009_low.jpg\"><\/a><\/p>\n\n\n\n<figure class=\"wp-block-image\"><a href=\"https:\/\/asocimed.cl\/portfolio\/chile-se-convierte-en\/#\"><img decoding=\"async\" src=\"https:\/\/asocimed.cl\/wp-content\/uploads\/2018\/06\/IMG_9052_low-270x270.jpg\" alt=\"Biopharmaceutical Competitiveness &amp; Investment (BCI) Survey\"\/><\/a><\/figure>\n\n\n\n<p><a href=\"https:\/\/asocimed.cl\/wp-content\/uploads\/2018\/06\/IMG_9052_low.jpg\"><\/a><\/p>\n\n\n\n<figure class=\"wp-block-image\"><a href=\"https:\/\/asocimed.cl\/portfolio\/chile-se-convierte-en\/#\"><img decoding=\"async\" src=\"https:\/\/asocimed.cl\/wp-content\/uploads\/2018\/06\/IMG_9061_low-270x270.jpg\" alt=\"Biopharmaceutical Competitiveness &amp; Investment (BCI) Survey\"\/><\/a><\/figure>\n\n\n\n<p><a href=\"https:\/\/asocimed.cl\/wp-content\/uploads\/2018\/06\/IMG_9061_low.jpg\"><\/a><\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Aso<\/h2>\n","protected":false},"excerpt":{"rendered":"<p>CHILE SE CONVIERTE EN UN POLO ATRACTIVO PARA LA INDUSTRIA BIOFARMAC\u00c9UTICA El Presidente de nuestra Instituci\u00f3n, el&nbsp;Dr. Eghon Guzm\u00e1n, fue invitado este 10 de mayo de 2018 a la presentaci\u00f3n del estudio 2017 Biopharmaceutical Competitiveness &amp; Investment (BCI) Survey.CHILE SE CONVIERTE EN UN POLO ATRACTIVOPARA LA INDUSTRIA BIOFARMAC\u00c9UTICA Y LAINVESTIGACI\u00d3N CL\u00cdNICA A NIVEL MUNDIALEstudio 2017 sobre Inversi\u00f3n y Competitividad en Biomedicina, patrocinado por PhRMA y&nbsp;FIFARMA, demostr\u00f3 que los pa\u00edses latinoamericanos podr\u00edan aumentar sustancialmente el nivel&nbsp;de inversi\u00f3n en la materia y que el pa\u00eds l\u00edder en la regi\u00f3n es Chile.&nbsp;En un encuentro organizado por la C\u00e1mara de la Innovaci\u00f3n Farmac\u00e9utica de Chile, (CIF) se&nbsp;present\u00f3 el estudio Biopharmaceutical Competitiveness and Investment (BCI) Survey 2017 que&nbsp;analiza, con base en la opini\u00f3n de 500 ejecutivos de las principales multinacionales que operan&nbsp;tanto en econom\u00edas desarrolladas como emergentes, el grado de atractivo y competitividad para&nbsp;el desarrollo de la industria biofarmac\u00e9utica, midiendo el grado de confianza que ellos tienen en 5&nbsp;\u00e1reas \u2013 que incluyen el grado de sofisticaci\u00f3n de la infraestructura local de investigaci\u00f3n y&nbsp;desarrollo, capacidades regulatorias, protecci\u00f3n de propiedad intelectual y din\u00e1micas de mercado&nbsp;\u2013 y traduci\u00e9ndolo en un puntaje cuantitativo.Descargar Comunicado de Prensa BCI SurveyImagenes del Evento. Aso<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[3],"tags":[],"class_list":["post-5928","post","type-post","status-publish","format-standard","hentry","category-noticias"],"_links":{"self":[{"href":"https:\/\/eghonguzmanb.cl\/site\/wp-json\/wp\/v2\/posts\/5928","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/eghonguzmanb.cl\/site\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/eghonguzmanb.cl\/site\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/eghonguzmanb.cl\/site\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/eghonguzmanb.cl\/site\/wp-json\/wp\/v2\/comments?post=5928"}],"version-history":[{"count":1,"href":"https:\/\/eghonguzmanb.cl\/site\/wp-json\/wp\/v2\/posts\/5928\/revisions"}],"predecessor-version":[{"id":5929,"href":"https:\/\/eghonguzmanb.cl\/site\/wp-json\/wp\/v2\/posts\/5928\/revisions\/5929"}],"wp:attachment":[{"href":"https:\/\/eghonguzmanb.cl\/site\/wp-json\/wp\/v2\/media?parent=5928"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/eghonguzmanb.cl\/site\/wp-json\/wp\/v2\/categories?post=5928"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/eghonguzmanb.cl\/site\/wp-json\/wp\/v2\/tags?post=5928"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}